Funding for this research was provided by:
Janssen KK
Article History
First Online: 2 August 2018
Compliance with Ethical Standards
:
: This work was supported by Janssen Pharmaceutical KK, the company that approved and funded the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
: JM and RS are affiliated with Janssen Pharmaceutical KK, a company that markets drugs for the treatment of RA. HK received research grants from Abbvie GK, Astellas Pharma, AstraZeneca K.K., Bristol– Myers K.K., Chugai Pharmaceutical Co, Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., Takeda Pharmaceutical Co. Ltd.; speaking fees from AbbVie GK, Astellas Pharma, Ayumi Pharamaceutical Corporation, Bristol– Myers K.K., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Novartis Pharma K.K., and Takeda Pharmaceutical Co. Ltd.; consultant fees from Abbvie GK, Eli Lilly Japan K.K., Novartis Pharma K.K., Nippon Kayaku Co. Ltd, Pfizer Japan Inc, UCB Pharma, Santen Pharmaceutical Co Ltd. and Sanofi K.K.
: We used the MDV database, which is a third-party database commercially available from Medical Data Vision Co., Ltd., Tokyo Japan:ExternalRef removed, TEL: + 81-3-5283-6911, FAX: + 81-3-5283-6811, e-mail: ebm_sales@mdv.co.jp. Accessing the data involves a fee.
: In the MDV database, the claim records of each patient are anonymously linked using de-identified codes, making it impossible to identify them.